News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
New Cancer Data May Be Tonic For Sickly Roche
October 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Oct 5 (Reuters) - Swiss drugmaker Roche (ROG.VX), battered by recent setbacks for key medicines, is banking on a batch of upcoming clinical trial data to restore belief in its pipeline.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Roche
MORE ON THIS TOPIC
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
September 24, 2026
·
2 min read
·
Gabrielle Masson
Eye disease
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
September 24, 2026
·
2 min read
·
Annalee Armstrong
Deals
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
September 24, 2026
·
2 min read
·
Gabrielle Masson
IN PARTNERSHIP WITH CURIUM
How radioligand therapy is rewriting cancer care
September 24, 2026
·
1 min read
·
Jennifer C. Smith-Parker
